Patents by Inventor Gene Hung

Gene Hung has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Thyroid hormone receptor agonists and uses thereof
    Patent number: 11964964
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
    Type: Grant
    Filed: May 28, 2019
    Date of Patent: April 23, 2024
    Assignee: XIZANG HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Bohan Jin, Gene Hung, Qing Dong
  • Methods and compositions for inhibiting PMP22 expression
    Patent number: 11959080
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.
    Type: Grant
    Filed: October 4, 2021
    Date of Patent: April 16, 2024
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
  • SUBSTITUTED 1,2,4-TRIAZOLES AS INTERMEDIATES IN THE SYNTHESIS OF TYK2 INHIBITORS
    Publication number: 20230391751
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: June 15, 2023
    Publication date: December 7, 2023
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Compositions for modulating Ataxin 2 expression
    Patent number: 11834660
    Abstract: Disclosed herein are antisense compounds and methods for decreasing Ataxin 2 mRNA and protein expression. Such methods, compounds, and compositions are useful to treat, prevent, or ameliorate Ataxin 2 associated diseases, disorders, and conditions. Such Ataxin 2 associated diseases include spinocerebellar ataxia type 2 (SCA2), amyotropic sclerosis (ALS), and parkinsonism.
    Type: Grant
    Filed: August 4, 2021
    Date of Patent: December 5, 2023
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Susan M. Freier, Gene Hung, C. Frank Bennett
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230357273
    Abstract: Described herein are compounds of Formula (I) that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: September 16, 2021
    Publication date: November 9, 2023
    Inventors: Bohan JIN, Qing DONG, Gene HUNG
  • Substituted 1,2,4-triazoles as intermediates in the synthesis of TYK2 inhibitors
    Patent number: 11731956
    Abstract: Described herein are compounds, for example, 1,2,4-triazole-substituted N-heteroaryl amines, that are useful in treating a TYK2-mediated disorder. In some embodiments, the TY-K2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Grant
    Filed: August 19, 2022
    Date of Patent: August 22, 2023
    Assignee: Alumis Inc.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Modulation of Huntingtin Expression
    Publication number: 20230023015
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: July 18, 2022
    Publication date: January 26, 2023
    Inventors: Gene Hung, C. Frank Bennet, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20230021554
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: August 19, 2022
    Publication date: January 26, 2023
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • SUBSTITUTED PYRIDINES AS TYK2 INHIBITORS
    Publication number: 20230023761
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: April 28, 2021
    Publication date: January 26, 2023
    Inventors: Bohan JIN, Qing DONG, Gene HUNG, Stephen W. KALDOR
  • Modulation of Huntington expression
    Patent number: 11421231
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Grant
    Filed: October 12, 2020
    Date of Patent: August 23, 2022
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • METHODS AND COMPOSITIONS FOR INHIBITING PMP22 EXPRESSION
    Publication number: 20220251553
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.
    Type: Application
    Filed: October 4, 2021
    Publication date: August 11, 2022
    Applicant: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20220235035
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: April 5, 2022
    Publication date: July 28, 2022
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • TYK2 INHIBITORS AND USES THEREOF
    Publication number: 20220177486
    Abstract: Described herein are compounds that are useful in treating a TYK2-mediated disorder. In some embodiments, the TYK2-mediated disorder is an autoimmune disorder, an inflammatory disorder, a proliferative disorder, an endocrine disorder, a neurological disorder, or a disorder associated with transplantation.
    Type: Application
    Filed: March 10, 2020
    Publication date: June 9, 2022
    Inventors: Bohan JIN, Qing DONG, Gene HUNG
  • TERPINOID DERIVATIVES AND USES THEREOF
    Publication number: 20220017566
    Abstract: Described herein are terpinoid derivatives as NRF2 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of inflammatory diseases.
    Type: Application
    Filed: September 23, 2019
    Publication date: January 20, 2022
    Inventors: Bohan JIN, Qing DONG, Gene HUNG, Stephen W. KALDOR
  • Methods and compositions for inhibiting PMP22 expression
    Patent number: 11136577
    Abstract: The present embodiments provide methods, compounds, and compositions useful for inhibiting PMP22 expression and for treating, preventing, or ameliorating a disease associated with PMP22.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: October 5, 2021
    Assignee: Ionis Pharmaceuticals, Inc.
    Inventors: Gene Hung, Holly Kordasiewicz, Hien Thuy Zhao, Eric E. Swayze
  • Substituted pyridines as TYK2 inhibitors
    Patent number: 11053219
    Abstract: Described herein are pyridine compounds of Formula (XIII) that are useful in treating a TYK2-mediated disorder.
    Type: Grant
    Filed: July 24, 2020
    Date of Patent: July 6, 2021
    Assignee: Esker Therapeutics, Inc.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Stephen W. Kaldor
  • Autotaxin inhibitors and uses thereof
    Patent number: 11040972
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with autotaxin activity. The methods and compositions disclosed herein include the use of at least one autotaxin inhibitor compound.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: June 22, 2021
    Assignee: SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Bohan Jin, Qing Dong, Gene Hung, Yao Li
  • Apoptosis signal-regulating kinase inhibitors and uses thereof
    Patent number: 11034671
    Abstract: Described herein are ASK1 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of blood disease, autoimmune disorders, pulmonary disorders, hypertension, inflammatory diseases, fibrotic diseases, diabetes, diabetic nephropathy, renal diseases, respiratory diseases, cardiovascular diseases, acute lung injuries, acute or chronic liver diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: September 7, 2018
    Date of Patent: June 15, 2021
    Assignee: SICHUAN HAISCO PHARMACEUTICAL CO., LTD.
    Inventors: Bohan Jin, Qing Dong, Gene Hung
  • MODULATION OF HUNTINGTIN EXPRESSION
    Publication number: 20210139900
    Abstract: Provided herein are methods, compounds, and compositions for reducing expression of huntingtin mRNA and protein in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate Huntington's disease, or a symptom thereof.
    Type: Application
    Filed: October 12, 2020
    Publication date: May 13, 2021
    Inventors: Gene Hung, C. Frank Bennett, Susan M. Freier, Holly Kordasiewicz, Lisa Stanek, Don W. Cleveland, Seng H. Cheng, Lamya Shihabuddin
  • THYROID HORMONE RECEPTOR AGONISTS AND USES THEREOF
    Publication number: 20210115022
    Abstract: Described herein are methods and compositions for the treatment of conditions, diseases, or disorders associated with thyroid hormone receptor activity. The methods and compositions disclosed herein include the use of at least one thyroid hormone receptor agonist.
    Type: Application
    Filed: May 28, 2019
    Publication date: April 22, 2021
    Inventors: Bohan JIN, Qing DONG, Gene HUNG